Brokers Set Expectations for AQST FY2024 Earnings

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Cantor Fitzgerald issued their FY2024 EPS estimates for Aquestive Therapeutics in a report issued on Tuesday, December 17th. Cantor Fitzgerald analyst K. Kluska expects that the company will post earnings of ($0.45) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $17.00 price target on the stock. The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.47) per share.

A number of other equities analysts also recently commented on AQST. Leerink Partners upped their target price on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a report on Friday, October 25th. JMP Securities reissued a “market outperform” rating and set a $9.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research report on Wednesday, November 6th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Aquestive Therapeutics currently has an average rating of “Buy” and an average target price of $11.00.

Aquestive Therapeutics Price Performance

AQST opened at $3.46 on Thursday. Aquestive Therapeutics has a one year low of $1.84 and a one year high of $6.23. The business has a 50 day simple moving average of $4.76 and a two-hundred day simple moving average of $4.07. The firm has a market capitalization of $315.48 million, a price-to-earnings ratio of -7.69 and a beta of 2.62.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings data on Monday, November 4th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The firm had revenue of $13.54 million for the quarter, compared to analysts’ expectations of $12.69 million. During the same period last year, the business posted ($0.03) earnings per share.

Institutional Investors Weigh In On Aquestive Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. nVerses Capital LLC purchased a new position in shares of Aquestive Therapeutics in the 3rd quarter worth about $28,000. Victory Capital Management Inc. purchased a new stake in shares of Aquestive Therapeutics during the second quarter valued at approximately $27,000. Harvey Capital Management Inc. bought a new stake in shares of Aquestive Therapeutics during the third quarter valued at approximately $88,000. Intech Investment Management LLC purchased a new position in Aquestive Therapeutics in the 3rd quarter worth approximately $90,000. Finally, BNP Paribas Financial Markets lifted its position in Aquestive Therapeutics by 252.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 18,826 shares of the company’s stock valued at $94,000 after acquiring an additional 13,481 shares in the last quarter. 32.45% of the stock is owned by institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.